Cell therapy doesn't give the body a "substance" — it gives it an army. We pull a patient's own white blood cells out, fit them with new weapons that recognize the face of their cancer, and send them back in to hunt. The result: some blood-cancer patients whom every drug had failed go into remission for years from a single treatment. But this miracle has a price — both the steep $400,000–500,000 per dose and the difficulty of having to "make a new drug each time, for each individual patient." This chapter walks through how it works, why it changed the game, who owns the market, and the future trying to make the "living drug" cheaper and genuinely within reach.
Contains
Theme index· base 100 · USD total return
No index history for this theme yet.
Why is Cell Therapy (CAR-T & beyond) moving?
Latest
▲3▼1
Safety pauses hit CAR-T, but new data and FDA support advance the field
▼
Novartis and BMS pause CAR-T trials after patient deaths Novartis paused eight CAR-T trials in autoimmune and neurological diseases after three patient deaths from a severe immune reaction, and Bristol-Myers Squibb paused enrollment in its competing CAR-T as a precaution. This safety scare could slow development in new disease areas and invite tougher regulation.
This is the biggest new negative force this period, directly hitting confidence in CAR-T expansion beyond cancer.
▲
J&J's CARVYKTI shows long-lasting remissions in myeloma Johnson & Johnson reported that half of early-line myeloma patients treated with CARVYKTI had five years with no need for further treatment. This validates the one-time CAR-T treatment model and supports moving it earlier in care, strengthening the long-term case for cell therapy.
This new data shows CAR-T can deliver durable, treatment-free remissions, a key proof point for the theme.
▲
FDA platform designation for Precigen's AdenoVerse The FDA granted a platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, which underpins its approved PAPZIMEOS therapy. This regulatory recognition can speed future products and signals official support for cell and gene therapy platforms, boosting the sector's outlook.
A new regulatory win that lowers development risk and encourages platform-based cell therapy investment.
▲
BMS's arlo-cel meets Phase 2 goal in multiple myeloma Bristol-Myers Squibb's arlo-cel met its primary endpoint in a Phase 2 trial for heavily pretreated multiple myeloma patients, with strong response rates. This adds another validated CAR-T candidate in blood cancer, reinforcing the technology's potential even as safety concerns linger elsewhere.
New positive clinical data that offsets some of the negative safety news and shows continued progress in oncology.
Q3 2026
▲2▼1
Cell therapy broadens beyond CAR-T, but safety setbacks hit hard
▲
First Treg therapy approved, expanding cell therapy beyond CAR-T The first regulatory approval of a Treg therapy (Tregzi) marks a new category beyond CAR-T, opening potential treatments for autoimmune and inflammatory diseases. This broadens the field's scope and long-term opportunity.
It shows a major new product category that expands the cell therapy market beyond cancer.
▲
CAR-T sales surge and next-gen in vivo deals boom Legend's CARVYKTI hit $657M in sales, Autolus doubled revenue, and J&J, Lilly, and Gilead signed multibillion-dollar deals for in vivo CAR-T. This signals strong commercial traction and heavy investment in next-generation therapies.
It highlights the financial momentum and big pharma bets driving the sector.
▼
Safety setbacks halt trials and crush small-cap stocks Novartis halted eight CAR-T trials after three deaths, its shares fell 10%, BMS paused enrollment, Capricor faces likely FDA rejection, TScan cut 75% of staff, and Lakefront wound down. Safety concerns are a major near-term overhang.
It captures the biggest negative force that weighed on the sector during the quarter.
◆
China's fast approval lane and low-cost CAR-T pressure pricing China proposed a 30-day approval lane, which could speed innovation but also flood the market with low-cost CAR-T. Combined with bispecific rivals, this pressures pricing in the US and Europe, a headwind for Western developers.
It shows a key regulatory and competitive shift that affects global pricing dynamics.
News & notes movingCell Therapy (CAR-T & beyond)
United States
Cell Therapy (CAR-T & beyond)▲
Iovance Biotherapeutics Fair Value Raised to US$12.80 on Amtagvi Demand
The fair value estimate for Iovance Biotherapeutics has been raised to US$12.80 per share from US$10.00, according to Simply Wall St. The revision reflects stronger expectations for the Amtagvi launch, margin trends and upcoming data, with the revenue growth assumption shifting from 43.38% to 45.57% and the net profit margin assumption moving from 9.50% to 12.09%. H.C. Wainwright lifted its price target to US$20 from US$9, citing FY26 total revenue guidance of US$410m to US$420m tied to U.S. demand for Amtagvi and Proleukin, while Wells Fargo moved to US$18 from US$14 and Goldman Sachs pointed to an inflection in the Amtagvi launch and easing logistical challenges. Barclays flagged durability in second line lung cancer for lifileucel ahead of IOV-LUN-202 data, while UBS, which raised its target to US$7 from US$4 and remains Neutral, noted that a strong Amtagvi quarter and gross margin of 56% came alongside a 74% rally in the stock. The valuation model's future P/E multiple changed from 75.55x to 72.80x and the discount rate moved from 7.47% to 7.50%.
IOVA · Capital · Positive Multiple analysts raised price targets and fair value on stronger Amtagvi launch expectations, margin trends, and revenue guidance.
IOVA · Demand · Positive FY26 revenue guidance tied to U.S. demand for Amtagvi and Proleukin, with an inflection in the Amtagvi launch.
Cell and Gene Therapy Bio-Manufacturing Market to Reach $21.46 Billion by 2030
The global cell and gene therapy biomanufacturing market is projected to grow from $12.35 billion in 2025 to $13.83 billion in 2026, a compound annual growth rate of 12%, and to reach $21.46 billion by 2030 at a compound annual growth rate of 11.6% from 2026, according to the Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026 added to ResearchAndMarkets.com. Growth is being driven by the increasing commercialization of cell and gene therapies, demand for scalable viral vector production, wider adoption of personalized medicine, and expansion among contract development and manufacturing organizations, alongside automation, digitalization, and investment in modern biomanufacturing facilities. The report cites the American Society of Gene and Cell Therapy's finding that the number of gene therapies in Phase III development increased by 10% during the fourth quarter of 2023 compared with the previous quarter, the first quarterly increase since the third quarter of 2022. In May 2026, Andelyn Biosciences launched its LVV Curator platform to streamline lentiviral vector manufacturing, using a modular, prevalidated framework based on Curator methodology previously applied across more than 100 adeno-associated virus programs. In January 2024, Oxford Biomedica plc acquired ABL Europe SAS for $17.35 million, expanding its manufacturing presence in Europe and its viral vector development and production services. North America was the largest cell and gene therapy biomanufacturing market in 2025, while Asia-Pacific is forecast to be the fastest-growing region; companies featured include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, and Samsung Biologics Co. Ltd.
Ligand Pharmaceuticals Strikes US$47 Million AvenCell CAR-T Financing Deal
Ligand Pharmaceuticals has entered a US$47 million financing agreement with AvenCell Therapeutics, comprising up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell's CAR-T therapy programs. The deal deepens Ligand's royalty-focused model by adding potential royalty streams on AvenCell's current and future pipeline, further broadening its portfolio of over 200 partnered assets following the XOMA Royalty acquisition. The new milestone-linked exposure comes as Ligand faces partner execution questions, including a recent termination notice to Viking Therapeutics over the TR Beta program. Ligand's narrative projects $481.1 million in revenue and $273.9 million in earnings by 2029, with a fair value estimate of $342.82, a 9% upside to its current price. Before the AvenCell deal, the most optimistic analysts had already assumed revenue could reach about US$538 million and earnings about US$277 million by 2029.
Biotech & Genomic Medicine › Cell Therapy (CAR-T & beyond) Capital
LGND · Capital · Positive Ligand signs a US$47M financing deal with AvenCell, adding milestone-linked royalty exposure to its portfolio.
AvenCell Therapeutics · Capital · Positive AvenCell secures up to US$47M in Series C funding and milestone payments from Ligand for its CAR-T programs.
VKTX · Regulation · Negative Article notes Ligand recently issued a termination notice to Viking Therapeutics over the TR Beta program.
Bristol-Myers Squibb Reports Positive Phase 2 Results for Arlo-Cel in Multiple Myeloma
Bristol-Myers Squibb announced on September 8 positive Phase 2 results from its registrational QUINTESSENTIAL trial of arlocabtagene autoleucel, or arlo-cel, in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma. The trial met its primary endpoint, showing a statistically significant and clinically meaningful overall response rate along with strong complete response rates in heavily pretreated patients who had received three or more prior lines of therapy, and the safety profile was consistent with existing CAR T and GPRC5D-targeting therapies. The readout comes as BMS works to expand its Growth Portfolio against mature-brand erosion; in the second quarter the company reported a 6% revenue increase to $13.0 billion, with Growth Portfolio revenues up 15% to $7.6 billion, and management raised full-year 2026 revenue guidance to $49.0 to $50.0 billion and non-GAAP EPS expectations to $6.75 to $7.00. The company still faces generic competition in its Legacy Portfolio, which fell 4% to $5.4 billion in the quarter, while full-year operating expenses are projected at $16.5 billion and non-GAAP gross margins contracted from 72.6% to 71.4%. BMS said arlo-cel provides a potentially differentiated cell therapy platform to address severe unmet needs in oncology.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
BMY · Technology · Positive Positive Phase 2 results for arlo-cel in relapsed/refractory multiple myeloma met the primary endpoint, supporting a differentiated CAR T cell therapy platform.
Gilead Sciences Raises 2026 Guidance and Lifts Dividend 3.8%
Gilead Sciences has raised its 2026 sales outlook and lifted its quarterly dividend by 3.8%. The guidance change lands in a stock that already carries momentum, with a 90 day share price return of 19.46% and a year to date move of 24.12%, while longer-term holders have seen a 37.33% 1 year total shareholder return and triple digit total shareholder returns over 3 and 5 years. The most followed narrative on the company puts fair value at $128.38 against a last close of $150.93, implying the stock is around 18% overvalued even after factoring in the raised sales outlook and the stronger dividend signal. That view frames Gilead as a medium term compounder transitioning from a single-franchise HIV company into a multi-platform biopharma, with lenacapavir and Trodelvy as high-probability growth drivers and cell therapy and immunology as high-upside optionality, but it flags short term volatility tied to an investment phase and recent deal related charges. The same narrative could be knocked off course if key oncology or cell therapy trials disappoint or if acquisition integration drags longer than expected, while a discounted cash flow model points the opposite way, screening the stock as heavily undervalued at an estimated future cash flow value of $309.92.
FDA Grants Platform Technology Designation to Precigen's AdenoVerse Platform
The United States Food and Drug Administration granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The designation and the earlier PAPZIMEOS approval have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a three-year total shareholder return exceeding 4x, while the more recent 90-day share price return of 32.25% indicates momentum has been building. The stock last closed at $7.75, and the most followed analyst view puts fair value at $11, framing the rally as only a partial catch up. On that view, bearish analysts expect earnings to reach $253.7 million, or $0.68 per share, by about August 2029, up from $336.7 million of losses today, while more bullish analysts expect earnings as high as $363.7 million. On a sales-based measure, the stock trades at 32.4x sales against a US Biotechs group average closer to 12.1x and a fair ratio of 9.5x, a gap that points to valuation risk if sentiment or forecasts change.
Johnson & Johnson Reports New Myeloma and Arthritis Data for TECVAYLI, CARVYKTI and TREMFYA
Johnson & Johnson reported new clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA in multiple myeloma and axial psoriatic arthritis. The MajesTEC-3 results for TECVAYLI plus DARZALEX FASPRO in early line relapsed or refractory multiple myeloma point to a regimen that achieved an estimated 83% overall survival rate at 3 years and a 90% reduction in disease progression risk versus standard care. CARVYKTI's five year, treatment free remissions in 50% of CARTITUDE-2 cohort A patients without maintenance therapy highlight a one time cell therapy treatment model. TREMFYA data support an axial psoriatic arthritis label expansion. The company, a US$653.6b pharmaceuticals player, now faces execution tests including regulatory decisions on label expansions and how quickly guideline bodies and major cancer centers incorporate TECVAYLI combinations and CARVYKTI earlier in treatment.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Regulation
JNJ · Technology · Positive New clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA show strong efficacy and support label expansions.
Novartis Pauses Eight CAR-T Trials After Three Patient Deaths; Bristol Myers Halts Enrollment
Novartis AG paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis, after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction, as first reported by the Wall Street Journal on September 1, 2026. The pause does not cover the company's two ongoing rap-cel trials in lymphoma and leukemia, which continue. Bristol-Myers Squibb Company separately paused enrollment in its own competing CAR-T program, zola-cel, as a precaution after observing what it described as transient and reversible inflammatory events, with no reported deaths. Bristol-Myers informed regulators and researchers in early June but waited about three months before informing the broader public, while Novartis confirmed its pause only after an analyst noticed the halted trials in a public database and disclosed the deaths one week later. Hedge fund count for Novartis grew to 38 in the second quarter from 31 in the first, with position value rising to $3.66 billion from $3.02 billion, while Bristol-Myers holders fell to 74 from 83 and position value declined to $4.79 billion from $5.97 billion.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Competition
NOVN.SW · Regulation · Negative Novartis paused eight rap-cel CAR-T trials in autoimmune and neurological conditions after three patient deaths from a severe immune reaction.
BMY · Regulation · Negative Bristol-Myers paused enrollment in its competing CAR-T program zola-cel and delayed informing the public for about three months, drawing regulatory scrutiny.
CARVYKTI Delivers Five-Year Treatment-Free Remission in Half of Early-Line Myeloma Patients
Johnson & Johnson announced that a single infusion of CARVYKTI, also known as ciltacabtagene autoleucel or cilta-cel, left 50% of patients in early line relapsed or refractory multiple myeloma alive and progression-free for at least five years without maintenance therapy. The findings come from the initial subgroup of cohort A of the Phase 2 CARTITUDE-2 study, which enrolled 20 patients who had received one to three prior lines of therapy, were exposed to a proteasome inhibitor, and were refractory to lenalidomide. At a median follow-up of 60.7 months, the five-year overall survival rate was 69.2% and median progression-free survival was 60.5 months, with long-term remissions seen even among patients carrying high-risk cytogenetic features. The safety profile was consistent with the known profile of cilta-cel, with no new CAR T-cell-related neurotoxicity, though one patient developed acute myeloid leukaemia and two deaths occurred due to progressive disease and new cancer. The results were presented at the International Myeloma Society Annual Meeting and build on the durable, treatment-free remissions observed in the CARTITUDE-1 study, reinforcing that earlier treatment with cilta-cel may increase long-term remission and disease control.
JNJ · Technology · Positive CARVYKTI (cilta-cel) delivered five-year treatment-free remission in half of early-line myeloma patients in the CARTITUDE-2 trial, a positive clinical/R&D result for J&J's product.
MEDEZE secures GMDP certification from Thai FDA for Phase 1-2 human investigational cell therapy production
MEDEZE Group Public Company Limited, or MEDEZE, announced that its manufacturing facility passed an assessment under the Good Manufacturing Practice guidelines, receiving the GMDP PIC/S Certificate for Investigational Cell Therapy Product from the Food and Drug Administration, or FDA, covering the manufacture of modern medicines for Phase 1 and Phase 2 human research in the biological products category, specifically the cell therapy product group Mesenchymal Stem Cells (Human Adipose Tissue-Derived MSC) for clinical research. Pharmacist Supatra Boonserm, Secretary-General of the Food and Drug Administration, said at the certificate presentation ceremony that the FDA has a policy of supporting advanced therapy medicinal products, or ATMPs, which represent the future of medical innovation, shifting treatment from symptom management to addressing root causes. Dr. Weerapon Khemarangsan, Chief Executive Officer of MEDEZE, stated that the scope of the certificate covers the manufacture of modern medicines for Phase 1 and Phase 2 human research and aligns with PIC/S GMP guidelines. The company has built its business foundation from cell storage, research, and manufacturing process development in order to connect knowledge in cell banking to the future development of cell therapy products. In addition to the GMDP certificate, MEDEZE has also passed cell bank standards under the criteria of the Department of Medical Sciences and holds AABB accreditation along with the ISO 9001:2015 quality management system, according to information the company previously disclosed.
Bristol Myers Squibb Growth Portfolio Hits 56% of Revenue as Zenbexus Wins FDA Approval
Bristol Myers Squibb's growth portfolio now accounts for 56% of total revenues, up from 51.8% a year earlier, after sales from those products rose 13% in the first half of 2026. The growth portfolio comprises Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyktu, Krazati and Cobenfy, while legacy products including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane make up the remaining 44% of revenues and face loss of exclusivity and generic competition. Opdivo Qvantig, the subcutaneous formulation of Opdivo, is now generating more than $1 billion in annualized revenues, and the FDA recently granted accelerated approval to iberdomide, in combination with daratumumab and hyaluronidase-fihj and dexamethasone under the brand name Zenbexus, for adults with multiple myeloma who have received at least one prior line of therapy, making it the first FDA-approved cereblon E3 ligase modulator. The Zacks Consensus Estimate for 2026 EPS has moved north to $6.91 from $6.34 in the past 60 days, while the 2027 EPS estimate has improved to $6.46 from $6.12. Bristol Myers shares have gained 13.4% year to date compared with the industry's growth of 8.5%, and the stock trades at 9.28X forward earnings versus the large-cap pharma industry's 18.23X.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
BMY · Capital · Positive 2026 EPS consensus rose to $6.91 from $6.34 and 2027 to $6.46 from $6.12 over the past 60 days.
BMY · Demand · Positive Growth portfolio products now 56% of revenue with 13% H1 2026 sales growth and Opdivo Qvantig surpassing $1B annualized.
BMY · Regulation · Positive FDA granted accelerated approval to iberdomide (Zenbexus) for multiple myeloma, the first approved cereblon E3 ligase modulator.
Cell Isolation Market Projected to Reach $13.51 Billion by 2032
The global cell isolation and cell separation market is projected to grow from USD 6.97 billion in 2026 to USD 13.51 billion by 2032, a compound annual growth rate of 11.39%, according to a new report from ResearchAndMarkets.com. The report profiles major players including Thermo Fisher Scientific, Bio-Rad Laboratories, Beckman Coulter, and Sartorius AG. Growth is driven by demand for high-purity, viable cells for single-cell sequencing, flow cytometry, and adoptive cell therapy, with the industry shifting from manual, open protocols toward automated, closed, digitally controlled systems. Artificial intelligence is cited as improving image-based cell recognition, flow cytometry gating, and quality control, while North America leads regional demand and Asia-Pacific expands through biotechnology and genomics investment in China, India, Japan, South Korea, and Australia.
Biotech & Genomic Medicine › CDMO / Contract Manufacturing ▲Demand
BIO · Demand · Positive Profiled as a major player in a cell isolation market growing 11.39% CAGR on rising demand for high-purity cells in sequencing and cell therapy.
SRT3.XETRA · Demand · Positive Profiled as a major player in the cell isolation market projected to nearly double by 2032 on rising end-user demand.
TMO · Demand · Positive Named among major players benefiting from expanding demand for cell isolation systems in single-cell sequencing and adoptive cell therapy.
Beckman Coulter · Demand · Positive Beckman Coulter named among major players in the cell isolation market expanding on demand for high-purity viable cells.
DIM.PA · Demand · Positive Sartorius subsidiary listed as a major player in the growing cell isolation and separation market.
Basecamp Research Raises $140M Series C to Advance AI-Designed Therapeutics
Basecamp Research has raised a $140M Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics toward clinical development. The oversubscribed round was led by S32, with participation from Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures, plus additional investment from senior leaders across pharma, biotech and global industry including André Hoffmann, Vice-Chairman of Roche. The London- and Boston-based company is applying EDEN, its biological foundation model, to in vivo cell therapy, pairing the model's ability to design long and complex DNA sequences with large serine recombinases that can precisely integrate them into the genome, an approach it says could transform treatment of cancer and autoimmune disease. Basecamp has demonstrated strong preclinical results across multiple modalities and disease areas, and has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer to expand its pharmaceutical partnerships. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, joins the Board of Directors. EDEN models are trained on the Trillion Gene Atlas, which Basecamp calls the world's largest proprietary biological AI training dataset, built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics and drawing on data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents.
Artificial Intelligence › AI Tooling, Data & MLOps Technology
Basecamp Research · Capital · Positive Basecamp Research raised a $140M oversubscribed Series C to train EDEN models and advance its AI-designed therapeutics pipeline.
NVDA · Capital · Positive NVIDIA participates in Basecamp Research's $140M Series C and co-built the Trillion Gene Atlas training dataset.
Anthropic · Capital · Positive Anthropic's Anthology Fund participated in Basecamp Research's $140M Series C round.
Autologous Stem Cell Gene Therapy Market to Reach $13.44 Billion by 2030
The global autologous hematopoietic stem cell gene therapy market is projected to grow from $5.23 billion in 2025 to $6.30 billion in 2026, a compound annual growth rate of 20.6%, and to reach $13.44 billion by 2030 at a 20.8% CAGR, according to the Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026 added to ResearchAndMarkets.com. Growth drivers include commercialization of gene-editing therapies, rising regulatory approvals, wider adoption of personalized medicine and expanding investment in cell and gene therapy infrastructure, alongside next-generation non-viral delivery platforms. In February 2024, Vertex Pharmaceuticals received conditional marketing authorization from the European Commission for CASGEVY, developed with CRISPR Therapeutics, for patients aged 12 and older with severe sickle cell disease and transfusion-dependent beta thalassemia. In October 2025, AGC Biologics partnered with Rarity Public Benefit Corporation to support development and Good Manufacturing Practice manufacturing of RDP-101 for adenosine deaminase severe combined immunodeficiency. North America was the largest regional market in 2025, while Asia-Pacific is expected to be the fastest-growing region; featured companies include Novartis AG, Vertex Pharmaceuticals, CSL Behring, Orchard Therapeutics, CRISPR Therapeutics, Rocket Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics and Prime Medicine.
China Sets 2030 Goal to Develop 25% of Global First-in-Class Drugs
Beijing has unveiled a five-year plan aimed at making China a global leader in drug innovation, with a target of developing 25% of the world's first-in-class drugs by 2030. The plan, issued in a joint notice from multiple government ministries, lays out 25 priority tasks spanning innovation capacity, research and technology, including expanded R&D, the use of AI and quantum computing in drug discovery, and the building of pharmaceutical ecosystems beyond pipelines. The government aims for the industry to reach 3.5tn yuan, or $520bn, in annual revenue by 2030, with 50 companies exceeding $1.5bn in annual revenue, and at least five Chinese drugs achieving global annual sales above $1bn. The notice singled out next-generation therapies including antibody-drug conjugates, cell and gene therapies, and CAR-T, along with vaccines and newer platforms such as mRNA, and included a section on industrialising traditional Chinese medicine. Citi analysts said the plan signals a shift from scale-driven growth toward innovation-driven, quality-oriented development, with a broad whole-value-chain policy push covering innovative drugs, medical devices, AI-driven drug discovery, and CDMO/CRO. The biomedical plan was released alongside counterparts for other strategic sectors, including integrated circuits, aerospace, the low-altitude economy, new energy storage and intelligent robotics.
Lakefront Biotherapeutics Plans 2027 Registrational Trials for Gamgertamig
Lakefront Biotherapeutics said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, in immune thrombocytopenia and autoimmune hemolytic anemia, with two additional autoimmune basket studies expected early that year. Speaking at Morgan Stanley's Global Healthcare Conference, Chief Executive Officer Henry Gosebruch said the company, previously known as Galapagos, has shifted focus from its legacy ex vivo CAR-T programs to a portfolio of four T-cell engager candidates following its acquisition of assets from Ouro Medicines in March. Gamgertamig is a BCMA-directed therapy that Gilead Sciences is expected to commercialize, with Lakefront receiving a royalty; Gilead contributed half of the Ouro deal consideration and about $5 billion to the company under a strategic alliance established in 2019 that has roughly three years remaining. Chief Financial Officer Aaron Cox said Lakefront expects to end the year with about €2 billion in cash, supported by Gilead funding, legacy royalties of approximately €15 million to €20 million annually related to Jyseleca, and tax-credit receipts of approximately €20 million to €35 million annually over the next several years. The company has largely completed the wind-down of its legacy cell-therapy operations, which had more than 650 employees and approximately $300 million in annual spending, and announced a €50 million share buyback in June that it expects to complete by year-end. The FDA has granted Orphan Drug Designation for gamgertamig in ITP, AIHA and pemphigus.
LKFT.AS · Capital · Positive Lakefront expects ~€2B year-end cash, Gilead funding, legacy royalties, tax credits, and a €50M buyback to be completed by year-end.
LKFT.AS · Technology · Positive Lakefront plans 2027 registrational trials for gamgertamig in ITP and AIHA, with FDA Orphan Drug Designation in three indications, advancing its lead T-cell engager.
GILD · Demand · Positive Gilead is expected to commercialize gamgertamig and contributed half of the Ouro deal consideration plus ~$5B under the strategic alliance, giving it rights to a pipeline asset heading into 2027 registrational trials.
Iovance Biotherapeutics Fair Value Estimate Raised to US$10.00 on Amtagvi Margin Progress
The analyst fair value estimate for Iovance Biotherapeutics has been raised from US$9.33 to US$10.00 per share, with recent price targets clustering in the US$10 to US$15 range. Barclays, TD Cowen and Mizuho have all lifted their price targets, with the upper end of recent moves reaching US$15, citing Amtagvi revenue trends, margin progression and the potential impact of upcoming data such as IOV-LUN-202. UBS pointed to Amtagvi revenue of US$91m and a 56% gross margin in Q2, supported by manufacturing efficiency and ATC performance, though it kept a Neutral rating and flagged that a 74% post Q2 rally has already reflected much of the near term upside. Barclays cited its physician survey and sees durability as a key differentiator for lifileucel in second line lung cancer ahead of the IOV-LUN-202 data in Q4, which it views as an important potential catalyst. The updated model also shows the projected net profit margin moving from 7.99% to about 9.50% and the future P/E multiple adjusting from 83.56x to about 75.55x.
Biotech & Genomic Medicine › CDMO / Contract Manufacturing ▲Supply
IOVA · Capital · Positive Analyst fair value estimate raised to US$10.00 and multiple price targets lifted on Amtagvi revenue trends and margin progression.
J&J Reaches $5.5 Billion Talc Settlement as Stock Climbs 18% in Three Months
Johnson & Johnson has agreed to a $5.5 billion settlement covering nearly all of its remaining talc litigation, a deal that requires participation by plaintiff firms representing at least 95% of the remaining claims before it becomes effective, with a first payment of up to $3 billion expected in 2027 and additional payments beginning in 2028. The agreement addresses roughly 76,000 lawsuits alleging that the company's talc-based baby powders contained asbestos and caused ovarian cancer. The news comes as JNJ stock has risen 18.3% in the past three months and 30.6% this year, against a 10.9% gain for the industry, supported by a raised 2026 outlook and Innovative Medicine segment sales up 6.2% on an organic basis in the first half of 2026 despite the loss of exclusivity of Stelara. That segment has now posted five consecutive quarters of sales above $15 billion, while J&J's newer cancer drugs Carvykti, Tecvayli, Talvey and Rybrevant/Lazcluze combined for $2.6 billion in first-half sales. MedTech grew more slowly, with second-quarter sales up 4.5% year over year to $8.93 billion, or 3.6% operationally, as Abiomed sales fell 2% and cardiovascular operational growth reached just 3.1%. J&J still targets around $100 billion in 2026 revenues, with $49.4 billion already booked in the first half, and the Zacks Consensus Estimate for 2026 earnings per share has edged up from $11.59 to $11.61 over the past 30 days.
Novartis Shares Plunge 10% as Del-desiran Fails Late-Stage Trial
Novartis shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1, marking its third clinical setback in a week. The earlier failures involved the cardiovascular drug pelacarsen and a pause of eight trials of the cell therapy rap-cel following three patient deaths. The decline erased roughly 24 billion Swiss francs, or about $29.6 billion, in market value and put Novartis on pace for one of its worst trading days in company history. Barclays had estimated peak annual sales of about $3.1 billion for del-desiran and assigned the drug a 60% probability of success after positive mid-stage results, and the failure raises questions about the $12 billion Avidity acquisition that brought the drug into Novartis' pipeline. Management reaffirmed its full-year financial guidance and maintained its target for 5% to 6% compound annual sales growth from 2025 through 2030, while the company reported successful late-stage results for remibrutinib in multiple sclerosis and expects more data later this year.
Biotech & Genomic Medicine › Cardiovascular & Heart-Failure Therapeutics ▼Technology
Biotech & Genomic Medicine › Gene & Cell Editing ▼Technology
NOVN.SW · Technology · Negative del-desiran failed its primary goal in a late-stage myotonic dystrophy type 1 trial, its third clinical setback in a week
GSK Buys Chimagen Trispecific T Cell-Engager for Multiple Myeloma
GSK agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, a drug asset the parties describe as a potential best in class trispecific T cell therapy. The deal expands GSK's blood cancer research portfolio and complements recent moves such as the Nuvalent acquisition that brought in Jideytro. Separately, GSK plans to close its German vaccine manufacturing site and consolidate production in Canada, with associated job reductions and supply chain changes. The key test will be whether GSK hits its stated timeline to move the trispecific T cell-engager into phase I trials in 2027, while advancing Jideytro's first line FDA submission planned for 2026. GSK is a £74.8b pharmaceuticals group that develops vaccines, specialty treatments and general medicines across major markets.
Anixa Biosciences Adds UPenn's Dr. Carmen Guerra to Cancer Advisory Board
Anixa Biosciences has appointed Dr. Carmen Guerra of the University of Pennsylvania to its Cancer Business Advisory Board. Dr. Guerra is the Ruth C. and Raymond G. Perelman Professor of Medicine and Professor of Biostatistics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania, and serves as Associate Director of Community Outreach and Engagement for the Abramson Cancer Center. Chief Executive Dr. Amit Kumar said her guidance will help as the company advances its breast cancer vaccine into a Phase 2 clinical trial and continues a Phase 1 trial of its ovarian cancer CAR-T therapy. Dr. Guerra's research focuses on increasing participation in cancer screening and clinical trials, and she oversees the Penn Medicine Colorectal Cancer Screening Navigation Program and the Breast and Cervical Cancer Early Detection Program. She is a member of the American Cancer Society Clinical Guidelines Development group and served on the society's national board of directors from 2016 to 2023 as Board Scientific Officer.
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) Talent
ANIX · Technology · Positive Appointed Dr. Carmen Guerra to its Cancer Advisory Board to guide its breast cancer vaccine Phase 2 and ovarian cancer CAR-T Phase 1 programs.
Cellectis Downgraded by Citizens as Gene Editing Pivot Delays CAR-T Catalysts
Citizens Capital Markets downgraded Cellectis to Market Perform from Market Outperform, sending the French biotech's ADRs lower for a second straight session on Tuesday. The downgrade follows the Paris-based company's strategic transformation to prioritize its in vivo gene editing candidates, HEAL-101 and HEAL-201, targeted at cardiovascular diseases, while discontinuing development of its CAR-T cell therapies lasme-cel and eti-cel. Citizens analyst Silvan Turkcan said the shift could delay related clinical catalysts to late 2027 or 2028, adding that early biomarkers may not be very helpful in de-risking a program. With Cellectis shares trading at roughly a 28% discount to its $169M worth of cash reserves, Turkcan argued the company is fairly valued in line with biotech peers facing similar uncertainties.
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Legend Biotech Corporation has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, following a comprehensive Board-led search process. Zhang succeeds Alan Bash, who served as Interim Chief Executive Officer since July 2026 and will resume his role as President, CARVYKTI. Zhang most recently served as Chief Commercial Officer for Novartis International, where she also led the company's China business and innovative medicines organization, and earlier held leadership positions at AstraZeneca, Pfizer, and McKinsey & Company. Frank Zhang, Chairman of the Board, said the Board concluded Ingrid is the right leader to guide Legend Biotech through its next phase of growth. Legend Biotech, with over 3,000 employees, is the largest standalone cell therapy company and develops and markets CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, with collaborator Johnson & Johnson.
Autolus Q2 Revenue Jumps 119% as AUCATZYL Sales Surge, Net Loss Narrows
Autolus Therapeutics reported second-quarter net product revenue of $45.7 million, up 119% from $20.9 million a year earlier and up from $26.2 million in the prior quarter, driven by its CD19-directed CAR T therapy AUCATZYL for adult relapsed or refractory B-cell precursor ALL. Management raised full-year 2026 guidance to $140 million to $150 million from a prior range of $120 million to $135 million, while gross margin jumped to 55% from 6% in the first quarter and negative margins throughout 2025. On August 3, the company signed a five-year, interest-only credit facility with Perceptive Advisors for up to $250 million, of which $75 million was funded at close on July 30, another $25 million is available at the company's option, and $150 million more is tied to future revenue milestones, extending projected cash runway to the second quarter of 2028. Despite the growth, Autolus posted a net loss of $39.1 million for the quarter, narrower than the $47.9 million loss a year earlier but bringing the six-month net loss to $110.7 million, as selling, general and administrative expenses climbed to $41.2 million from $30.3 million and cash, cash equivalents and marketable securities fell to $201.6 million at June 30 from $229.4 million at the end of March. Hedge fund ownership in Autolus fell to 11 funds in the most recent quarter from 14 in the quarter before, while short interest sits at 5.26% of float.
Perceptive Advisors · Capital · Positive Perceptive Advisors signed a five-year credit facility with Autolus for up to $250 million, a financing deal it is the lender on
Cellectis Posts 1H GAAP EPS of -$0.39, Revenue Down 52.2% to $14.45M
Cellectis reported a first-half GAAP loss of $0.39 per share, with revenue of $14.45 million, a decline of 52.2% year over year. The results were disclosed in a Cellectis press release. The company's shares trade under the ticker CLLS. No further financial details were provided in the release.
Bristol Myers' arlo-cel hits main goal in mid-stage multiple myeloma trial
Bristol-Myers Squibb Company said its experimental CAR-T cell therapy arlocabtagene autoleucel, or arlo-cel, met the main goal of a mid-stage trial in patients with advanced multiple myeloma who had already gone through four major classes of standard treatments, producing a statistically significant and clinically meaningful improvement in overall response rates. The therapy also met a key secondary goal, with some patients achieving complete elimination of detectable cancer, and Bristol Myers said the safety profile was in line with what would be expected from CAR-T and other GPRC5D-targeting therapies. The company has not yet released the detailed numbers and plans to present the full results at an upcoming medical conference. Arlo-cel works by modifying a patient's own immune cells so they can target GPRC5D on cancer cells, and the results strengthen Bristol Myers' position in the competitive multiple myeloma market, where Reuters cites roughly 36,000 new U.S. cases expected this year. Competition remains intense, with recent results from AbbVie showing strong potential for its experimental treatment etentamig in relapsed or refractory multiple myeloma, and investors still need the detailed clinical data before judging how strong and durable the benefits really are.
Biotech & Genomic Medicine › Oncology Therapeutics Competition
BMY · Technology · Positive Bristol Myers' arlo-cel CAR-T met the primary endpoint in a mid-stage multiple myeloma trial with statistically significant and clinically meaningful response improvements.
ABBV · Competition · Neutral AbbVie's experimental etentamig showed strong potential in relapsed/refractory multiple myeloma, a competitive mention against Bristol's arlo-cel.
TScan Therapeutics Cuts Workforce by 75% to Focus on Solid Tumors
TScan Therapeutics announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor (TCR-T) program targeting solid tumors. The Waltham, Massachusetts-based company plans to advance two product candidates into investigational new drug-enabling studies, one targeting PRAME and the other targeting MAGE-A4. TScan expects to present preclinical data in the first quarter of 2027, submit its first investigational new drug application in the third quarter of 2027, and begin Phase 1 development in the fourth quarter of 2027. The reorganization is expected to generate cumulative cost savings of approximately $55 million through the end of 2027, and the company's cash, cash equivalents, and marketable securities as of June 30, 2026 are expected to fund operations into the fourth quarter of 2027. As part of the restructuring, TScan is eliminating its internal manufacturing organization and reducing its research operations. TScan is also pausing further enrollment in its Phase 3 ALLOHA-2 study of TSC-101 for hematologic malignancies, citing insufficient capital to complete the trial; seven patients already enrolled will continue to be monitored. The company is actively seeking strategic partners for its hematologic malignancies program and is evaluating partnerships for its autoimmune program focused on HLA-B*27-associated disorders. TScan also provided updated data from Cohort C of its Phase 1 ALLOHA study, showing that all 13 patients currently being followed demonstrated complete donor chimerism, including two who had previously relapsed. Additional Cohort C data are expected in the fourth quarter of 2026, and data covering all patients treated with its commercial-ready manufacturing process are expected in the second quarter of 2027.
TCRX · Capital · Negative Workforce cut by 75% and pausing Phase 3 trial due to insufficient capital, but cost savings extend cash runway into Q4 2027.
Novartis Halts CAR-T Trials After Three Patient Deaths
Novartis has paused eight clinical trials of an experimental CAR-T therapy targeting autoimmune and neurological disorders after three patients died from a severe immune response, the Wall Street Journal reported. The Swiss pharmaceutical company temporarily halted the studies in late August and is conducting a comprehensive review of the safety events, which it describes as a known risk in CAR-T therapies. Novartis is working with independent safety boards overseeing each paused study and sharing information with regulators. Bristol-Myers Squibb has also paused similar trials of its CAR-T treatment in autoimmune disorders as a precautionary measure.
Johnson & Johnson Taps Sail Biomedicines in CAR-T Deal
Johnson & Johnson has struck a deal to collaborate with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases, paying $785 million upfront and up to $140 million in milestones, with an option to acquire Sail for $2.58 billion. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to $35.9 billion by 2032, a compound annual growth rate of 28.5%. Johnson already markets Carvykti for multiple myeloma, while Bristol-Myers Squibb's Breyanzi franchise targets B-cell lymphomas and leukemias. At the end of the second quarter, 117 hedge funds held Johnson stock, up from 113, while Bristol was held by 74, down from 83. Johnson's short interest stands at 0.90% of float, compared with 2.25% for Bristol.
Nanjing Xinjiekou Department Store posts first-half revenue of 2.89 billion yuan as dual-engine strategy gains traction
Nanjing Xinjiekou Department Store disclosed its 2026 semi-annual report on the evening of August 26, reporting first-half operating revenue of 2.89 billion yuan and total profit of 163 million yuan. The company adhered to its dual-engine strategy of "big health plus new consumption," with progress across its modern commerce, health and elderly care, and biomedical segments. In modern commerce, the company advanced store renovations, introduced first stores and benchmark brands, and created younger-oriented consumption scenarios. In health and elderly care, Ankangtong won 82 projects, while overseas subsidiary Natali completed the acquisition and integration of several UK elderly care companies. In biomedicine, Qilu Stem Cell completed filings for two new technologies, and Dendreon China's Provenge is in Phase III clinical follow-up. The company said it will continue to seize opportunities in the silver economy and the cell and gene therapy industry to promote high-quality development.
600682.CG · Capital · Positive Company reports first-half revenue of 2.89 billion yuan and total profit of 163 million yuan, indicating solid financial performance.
Natali · Capital · Positive Subsidiary Natali completed acquisition and integration of several UK elderly care companies, expanding its operations.
丹瑞中国 · Technology · Positive Dendreon China's Provenge is in Phase III clinical follow-up, a positive development in its pipeline.
安康通 · Demand · Positive Ankangtong won 82 projects, indicating strong demand for its health and elderly care services.
齐鲁干细胞 · Technology · Positive Qilu Stem Cell completed filings for two new technologies, advancing its biomedical segment.
Adicet Bio Advances Prula-cel and ADI-212 Pipeline
Adicet Bio is advancing its lead candidate prula-cel in autoimmune diseases and expects to report updated phase I data in the third quarter of 2026. The company plans to begin a pivotal study in lupus nephritis in the second half of 2026, subject to regulatory clearance, and will provide additional clinical updates for systemic sclerosis and rheumatoid arthritis later that year. Adicet also expects to submit a regulatory filing for ADI-212, a gene-edited cell therapy for metastatic castration-resistant prostate cancer, in the third quarter of 2026 and begin phase I enrollment in the fourth quarter. Over the past 30 days, analysts have narrowed the 2026 loss per share estimate for Adicet from $8.61 to $6.76, while widening the 2027 loss estimate from $3.71 to $5.64. The stock has risen 9.2% year to date, compared with an 11.1% gain for the industry.
Gilead Posts $11 Billion Pipeline Bet Loss Despite Core Growth
Gilead Sciences reported a large quarterly loss in fiscal Q2 2026 despite double-digit growth in its core business, driven by more than $11 billion in acquired research and development expenses. Product sales excluding Veklury rose 10% to $7.6 billion, with HIV sales up 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy at $967 million. The company recorded $11.2 billion in acquired in-process R&D charges, including $7 billion for Arcellx, $3.1 billion for Tubulis, and $1 billion for Ouro Medicines, resulting in a GAAP loss of $8.45 per share. Management raised the lower end of 2026 product-sales guidance to $30.1–$30.4 billion, while cash and marketable securities fell to $3.2 billion from $10.6 billion at the end of 2025. The FDA has accepted the application for anito-cel, with a target decision date of December 23, 2026.
Capricor slips after report on potential Deramiocel rejection
Capricor Therapeutics shares declined on Thursday after a STAT News report renewed concerns about a potential U.S. rejection of its lead candidate, Deramiocel. An FDA advisory panel declined to endorse the cell therapy last month, and the drug is under regulatory review for cardiomyopathy in Duchenne muscular dystrophy with a target action date of August 22. STAT senior writer Adam Feuerstein called the company's plan to submit open-label extension data from its Phase 3 HOPE-3 trial a stall tactic, adding that it is not clear why the company publicly maintains confidence in the drug. Capricor did not immediately respond to a request for comment.
CARsgen Therapeutics posts 62 million yuan half-year revenue as solid tumor CAR-T awaits market test
CARsgen Therapeutics disclosed its first-half 2026 results, reporting revenue of 62 million yuan, mainly from its autologous BCMA CAR-T product Zevorcabtagene Autoleucel. Thanks to higher sales of Zevorcabtagene Autoleucel, gross profit reached 42 million yuan, up 13 million yuan from 29 million yuan in the same period of 2025. Net loss for the period was 70.84 million yuan, compared with annual net losses of 748 million yuan, 798 million yuan and 98 million yuan from 2023 to 2025. With the approval in June 2026 of the world's first solid tumor CAR-T product, Satricabtagene Autoleucel, the market expects it to add new volume in the second half. Satricabtagene Autoleucel is listed at 990,000 yuan per dose. The company expects 200 orders in 2026 and forecasts peak sales of 2 billion yuan in the mainland China market, reaching that peak in about four to five years. As of the end of June 2026, the company had cash and cash equivalents of about 1.4 billion yuan, up 277 million yuan from 1.123 billion yuan at the end of 2025. The company judges that its existing capital reserves can support operations until 2030.
Medeze Group Public Company Limited, or MEDEZE, reported net profit for the second quarter of 2026 at 40.18 million baht, an increase of 5.81 million baht, or about 17%, from the previous quarter's net profit of 34.37 million baht, with total revenue of 170.31 million baht. Net profit has recovered continuously over the past four quarters, from 30.54 million, 36.43 million, and 34.37 million baht in the third quarter of 2025, the fourth quarter of 2025, and the first quarter of 2026, respectively. The company is the first and only one in Thailand to pass cell banking standards, along with standards and certifications including Por Yor 2, AABB, and ISO, and has joined the ATMPs Regulatory Sandbox to drive Thailand's stem cell innovation and advanced medical products. The company aims to receive GMP standards within the fourth quarter of 2026 and begin clinical trials to treat knee osteoarthritis and skin rejuvenation in 2027, before commercially producing cell culture media in 2028 to reduce imports, alongside expanding into the Philippine market.
WINMED second-quarter profit surges 237% on blood and cell therapy business
Winner Medical Public Company Limited, or WINMED, reported second-quarter net profit for fiscal 2026 of 6.4 million baht, up 237% from 1.9 million baht in the same period last year. Total revenue was 209 million baht, up 39% from 151 million baht. For the first six months, net profit was 9.6 million baht, up 20%, and total revenue was 362 million baht, up 17% from 309 million baht. Growth was driven by the medical blood recruitment business, which continued to expand, and the cell and molecular technology group, which delivered CliniMACS Prodigy and MACSQuant Analyzer instruments to government agencies for use in CAR-T cell therapy processes, along with higher revenue from reagents and blood cancer treatment products. The company also expanded its pathogen inactivation service, now used by more than 45 hospitals, and extended its mobile blood collection project, with more than 20 participating hospitals. It also launched Thailand's first mobile platelet donation bus to support future growth.
Iovance Biotherapeutics reported record second-quarter 2026 revenue of $99.3 million, driven by strong demand for its Amtagvi TIL therapy. Amtagvi revenue reached approximately $91 million, exceeding the company's guidance range of $79 million to $81 million and up 51% sequentially. Gross margin hit an all-time high of 56%, up from 41% in the first quarter. The company is reviewing its full-year 2026 total revenue guidance of $350 million to $370 million and expects to provide an update during the third quarter. Iovance also announced FDA Fast Track designation for lifileucel in two advanced soft tissue sarcomas and reported a 40% confirmed objective response rate in a Phase 2 endometrial cancer trial.
Autolus Q2 net loss narrows as AUCATZYL sales surge 119%
Autolus Therapeutics reported a narrower second-quarter net loss as AUCATZYL product revenue surged 119% to $45.69 million. Net loss shrank to $39.11 million, or $0.15 per share, from $47.92 million, or $0.18 per share, a year earlier. The company raised its full-year 2026 AUCATZYL net product revenue guidance to $140 million to $150 million, up from a prior range of $120 million to $135 million. Autolus expects longer-term follow-up data from the CARLYSLE Phase 1 trial of obe-cel in severe refractory systemic lupus erythematosus by year-end 2026. Cash, cash equivalents and marketable securities totaled $201.6 million as of June 30, 2026, and combined with $100 million in credit facility proceeds, the company expects its cash balance to fund operations into the second quarter of 2028.
Legend Biotech Turns Profitable In Q2 As CARVYKTI Sales Jump 50%
Legend Biotech Corporation reported a second-quarter profit of $33.2 million, or $0.09 per share, swinging from a loss of $125.4 million a year earlier, driven by a 50% surge in CARVYKTI sales to $657 million. Total revenue climbed 52% to $387.5 million, with collaboration revenue from the Johnson & Johnson partnership reaching $326.1 million. The company also highlighted positive clinical updates for pipeline programs LB2501 and LB2102, and ended the quarter with $965 million in cash, which it expects to fund operations beyond 2026.
Legend Biotech surges 6% after Q2 revenue beat and first-ever profitable quarter
Legend Biotech shares rose 6% after the company reported second-quarter 2026 results that beat estimates and delivered its first quarter of company-wide profitability. Total revenue reached $387.5 million, up 52% year over year and above the $362.81 million consensus, while adjusted earnings per share of $0.16 more than doubled the roughly $0.07 analyst forecast. CARVYKTI net trade sales hit $657 million, a 50% increase, and management reiterated peak annual sales potential above $5 billion for the CAR-T therapy co-developed with Johnson & Johnson's Janssen unit. The company also reported a pipeline milestone with first clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, showing a 100% overall response rate at the higher dose level. Interim CEO Alan Bash emphasized continuity following the departure of former CEO Ying Huang, while the Wall Street consensus price target of $52.10 remains well above current levels.
